Cargando…
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons
Biologic therapies have become central to the long-term management of many chronic diseases, including inflammatory rheumatic diseases. Over recent years, the development and licensing pathways for biosimilars have become more standardized, and several biosimilars have been made available for patien...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850213/ https://www.ncbi.nlm.nih.gov/pubmed/28903542 http://dx.doi.org/10.1093/rheumatology/kex276 |